Understanding and treating immune issues in children with sepsis
Official title: Targeting Immune Dysregulated Endotypes in Sepsis (TIDES)
Funded at Children's Hosp of Philadelphia · NIH-11114454 · Data updated 2026-11-12
This study is looking at how children's immune systems react during sepsis, a serious condition, to find better ways to treat them based on their unique needs.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Children's Hosp of Philadelphia NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | June 1, 2025 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $179,475 |
| NIH project number | 1K23GM159013-01 |
| Project ID | NIH-11114454 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children diagnosed with sepsis who are hospitalized and experiencing immune dysregulation.
✕Less likely to help
Patients who are not children or those who do not have a diagnosis of sepsis may not benefit from this research.
What this research studies
This research focuses on pediatric sepsis, a critical condition that leads to organ failure in children due to immune system dysfunction. The team aims to identify specific molecular changes in the immune response of children suffering from sepsis, which can help in tailoring treatments to individual patients. By analyzing blood samples and using advanced techniques, they hope to discover which immune dysregulations can be reversed and how to predict the severity of the condition in real-time. This approach could lead to more effective and personalized treatment strategies for affected children.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and treatment outcomes for children suffering from sepsis.
How similar studies have gone: Previous research has shown promise in using molecular profiling to guide treatment in sepsis, indicating that this approach could lead to significant advancements in care.
Where this research is happening
-
Children's Hosp of Philadelphia
Philadelphia, United States Active
Researchers
- Principal investigator: Lindell, Robert B — Children's Hosp of Philadelphia
- Study coordinator: Lindell, Robert B
Related research
Other NIH-funded projects on the same topics.
-
Role of blood flow mechanics and transfusion in sepsis-related tiny-cl vessel clots
A patient-focused look at how red blood cell flow and transfusions might influence tiny blood vessel clots and organ problems in sepsis.
-
STeroids and enhanced Antibiotics for sepsis in Africa with HIV/TB (STARS)
This grant tests whether adding steroids and stronger antibiotics helps adults with severe sepsis tied to HIV/TB in areas with high TB rates.
-
Steroids and better antibiotics for sepsis in people with AIDS in Africa
This study tests whether adding hydrocortisone and stronger antibiotics can improve survival for adults with sepsis who also have AIDS or advanced immune suppression in regions with high TB.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Role of MMP3 in heart dysfunction during sepsis
This research tests whether blocking MMP3 can protect the heart and improve survival during sepsis in adults.
-
Sepsis patient care guided by Ugandan-wide immune profiling
A large NIH-funded study will map how the immune system behaves during sepsis in people in Uganda to improve personalized care for sepsis patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.